- Home
- RIGL vs RGP Comparison
RIGL vs RGP Comparison
Compare RIGL & RGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- RGP
- Stock Information
- Founded
- RIGL 1996
- RGP 1996
- Country
- RIGL United States
- RGP United States
- Employees
- RIGL N/A
- RGP N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- RGP Business Services
- Sector
- RIGL Health Care
- RGP Consumer Discretionary
- Exchange
- RIGL Nasdaq
- RGP Nasdaq
- Market Cap
- RIGL 247.1M
- RGP 266.4M
- IPO Year
- RIGL 2000
- RGP 2006
- Fundamental
- Price
- RIGL $22.07
- RGP $8.80
- Analyst Decision
- RIGL Buy
- RGP Hold
- Analyst Count
- RIGL 4
- RGP 3
- Target Price
- RIGL $31.13
- RGP $13.00
- AVG Volume (30 Days)
- RIGL 151.9K
- RGP 301.3K
- Earning Date
- RIGL 11-07-2024
- RGP 01-02-2025
- Dividend Yield
- RIGL N/A
- RGP 6.36%
- EPS Growth
- RIGL N/A
- RGP N/A
- EPS
- RIGL 0.22
- RGP 0.36
- Revenue
- RIGL $156,374,000.00
- RGP $599,567,000.00
- Revenue This Year
- RIGL $38.26
- RGP N/A
- Revenue Next Year
- RIGL $24.21
- RGP $14.18
- P/E Ratio
- RIGL $99.67
- RGP $24.19
- Revenue Growth
- RIGL 19.95
- RGP N/A
- 52 Week Low
- RIGL $7.48
- RGP $7.90
- 52 Week High
- RIGL $22.85
- RGP $14.63
- Technical
- Relative Strength Index (RSI)
- RIGL 83.76
- RGP 55.81
- Support Level
- RIGL $13.91
- RGP $7.90
- Resistance Level
- RIGL $14.70
- RGP $9.04
- Average True Range (ATR)
- RIGL 1.04
- RGP 0.24
- MACD
- RIGL 0.50
- RGP 0.13
- Stochastic Oscillator
- RIGL 91.59
- RGP 78.95
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.